DON DIZON: Hi. Don Dizon. I’m a professor of medicine and professor of surgery at Brown University, and I treat pelvic cancer. And I’m here at ASCO ’23. One of the studies presented was the SHAPE Trial, analyzing individuals with early cervical cancer. This was a disease that was limited to the cervix– not very big.

The complex surgical procedure known as radical hysterectomy involves specialized training and includes removing the cervix, uterus, and pelvic sidewalls. By solely removing the cervix and uterus, without extending the pelvic area and side wall, the procedure becomes less complex

This study tested that simpler procedure versus the standard radical procedure and ultimately showed that at three years, the survival outcomes were the same and that quality of life was better with a simple hysterectomy, particularly as it related to sexual quality of life.

DON DIZON: Hi, I’m Don Dizon. I’m a professor of medicine and a professor of surgery at Brown University. And I treat pelvic cancer. One of the studies presented at ASCO 23 was the overall survival results if you add a checkpoint inhibitor to the treatment of metastatic cervical cancer.

In this study, researchers randomly assigned women with metastatic or advanced cervical cancer to receive standard treatment with chemotherapy, along with the drug bevacizumab, which blocks the specific protein vascular endothelial growth factor, and the checkpoint inhibitor pembrolizumab.

Updated analyses reveal that adding pembrolizumab to the standard two-drug or three-drug combination improves overall survival by approximately a year. So these data truly suggest, where it’s available, chemotherapy with pembrolizumab plus or minus the use of bevacizumab is the standard of care for people living with metastatic cervical cancer.

DON DIZON: This is Don Dizon. I’m a professor of medicine and professor of surgery at Brown University, and I treat pelvic cancers.

At ASCO ’23, researchers presented the MIRASOL trial, which involved individuals with recurrent ovarian cancer. The trial focused on those whose disease relapsed soon after receiving standard platinum and taxane combination treatment. The intent is to cure them. If the disease recurs within approximately six months or less, it is referre to as platinum resistance.

The MIRASOL trial took people with platinum-resistant ovarian cancer and treated them with a novel drug called mirvetuximab or standard chemotherapy. And this study showed overall survival benefits with this new drug, mirvetuximab, over standard of care chemotherapy, importantly, in a selected group of people whose tumors expressed a protein called folate receptor alpha. So again, for those people who had high-expressing folate receptor alpha ovarian cancer whose disease recurred early after chemotherapy, mirvetuxim

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here